Navigation Links
Telik Announces Presentation at ASCO Annual Meeting
Date:5/21/2009

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL.

Details of the presentation are as follows:

           -- Abstract #5552 - General Poster Session, Gynecologic Cancer;
              Sunday, May 31, 2009, 2:00-6:00pm EDT; Level 2, West Hall C

              Title:  "Randomized phase III study of canfosfamide (C, TLK286)
              plus pegylated liposomal doxorubicin (PLD) versus PLD as
              second-line therapy in platinum (P) refractory or resistant
              ovarian cancer (OC)."

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
2. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
4. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
5. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
6. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
7. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
10. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
11. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 Quantum Radiology,s Mobile Breast Center ... interpretation directly to women at the workplace, thereby maximizing ... as Delta Air Lines and SunTrust Bank, and community ... component of wellness initiatives. "I think it,s ... enables them to have a mammogram without taking a ...
(Date:12/2/2016)... CORDOBA, Spain , Dec. 2, 2016 ... additional natural sources apart from those derived from C. ... Córdoba, the Universita` di Napoli Federico II , ... have created the first comprehensive, critical, integrated and unified ... The article focuses on the remarkable chemical ...
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction ... the Academy of Managed Care Pharmacy (AMCP), has ... can better address the opioid addiction crisis, including ... Therapies (MAT). ATAG,s newly released paper, ... Access to Naloxone," addresses many issues around gaps ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Lori ... Greenberg Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st ... Greenberg Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Advanced Inc., ... it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial ... Advanced, Inc. , Jason brings extensive financial and operational leadership experience to Advanced ...
(Date:12/2/2016)... PITTSBURGH, PA (PRWEB) , ... December 02, 2016 , ... ... or struggling through rehabilitation of an injury, patients must find the one that works ... for his pain, he created a machine that worked and decided to share it ...
(Date:12/2/2016)... Delaware (PRWEB) , ... December 02, 2016 , ... ... released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps ... sample entry through labeling, storing, shipping and disposal. The new version is a ...
(Date:12/2/2016)... Texas (PRWEB) , ... December 02, 2016 , ... Yisrayl ... that delves into how this current generation fits into Bible Prophecy. Yisrayl says this ... various facts pointing to this conclusion, showing how the details line up exactly with ...
Breaking Medicine News(10 mins):